BioCardia

BioCardia R&D per Employee

The R&D Spending per Employee of BioCardia (BCDA) as of Nov 20, 2026 is 291,882.35 USD. In the previous year, R&D Spending per Employee was 258,058.82 USD — a change of 13.11% (higher).

R&D per Employee

291,882.35USD

YoY

13.11%

Last updated:

R&D Spending per Employee of BioCardia is 2025 291,882.35 USD. R&D Spending per Employee of BioCardia was 2024 258,058.82 USD. It decreases by 13.11% higher compared to the previous year.

The BioCardia R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
497,235.29 USD
Jan 1, 2019
503,647.06 USD
Jan 1, 2020
577,000.00 USD
Jan 1, 2021
503,411.76 USD
Jan 1, 2022
519,647.06 USD
Jan 1, 2023
454,470.59 USD
Jan 1, 2024
258,058.82 USD
Jan 1, 2025
291,882.35 USD
The BioCardia R&D per Employee history
YEARR&D per EmployeeYoY
291,882.35USD+13.11%
258,058.82USD-43.22%
454,470.59USD-12.54%
519,647.06USD+3.23%
503,411.76USD-12.75%
577,000.00USD+14.56%
503,647.06USD+1.29%
497,235.29USD+45.77%
341,117.65USD+74.14%
195,882.35USD+119.37%
89,294.12USD0.00%
89,294.12USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

R&D Spending per Employee of BioCardia is 291,882.35 USD in 2025.

R&D Spending per Employee of BioCardia changed from 258,058.82 USD to 291,882.35 USD, representing a 13.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee BioCardia since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioCardia

All Key Metrics — BioCardia